following a resubmission:
ocriplasmin (Jetrea®) is accepted for restricted use within NHS Scotland.
Indication under review: In adults for the treatment of vitreomacular traction, including when associated with macular hole of diameter less than or equal to 400 microns.
SMC restriction: patients with vitreomacular traction plus macular hole, regardless of whether they have epiretinal membrane formation, and in patients with vitreomacular traction alone (no epiretinal membrane and no macular hole).
In two randomised, controlled double-masked studies, significantly more patients treated with ocriplasmin than placebo achieved resolution of vitreomacular adhesions which may correlate with improved visual acuity.
Download detailed advice297KB (PDF)
- Medicine name:
- ocriplasmin (Jetrea)
- SMC ID:
- In adults for the treatment of vitreomacular traction, including when associated with macular hole of diameter less than or equal to 400 microns.
- Pharmaceutical company
- Thrombogenics NV
- BNF chapter
- Submission type
- Date advice published
- 11 August 2014
Ocriplasmin (Jetrea) is now only available as a 0.375mg/0.3mL ‘ready-diluted’ formulation, which is manufactured by Oxurion NV, formerly known as ThromboGenics NV. The new formulation is out of SMC remit since there is no associated change to the licensed indication and it costs the same as the previous formulation (0.5mg/0.2mL concentrate for solution for injection) which it replaces. SMC advice for ocreplasmin (Jetrea) (892/13) remains valid.